Phase 3 Cholangiocarcinoma Clinical Trials
9 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–9 of 9 trials
Recruiting
Phase 3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Cholangiocarcinoma
Servier Affaires Médicales220 enrolled84 locationsNCT05876754
Recruiting
Phase 2Phase 3
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Solid Tumor, AdultAdvanced Intrahepatic Cholangiocarcinoma
Hutchmed235 enrolled1 locationNCT04353375
Recruiting
Phase 2Phase 3
Trop2-targeted immunoPET Imaging of Solid Tumors
Liver CancerOvarian CancerCervical Cancer+11 more
RenJi Hospital400 enrolled1 locationNCT06851663
Recruiting
Phase 3
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Pancreatic CancerCholangiocarcinomaPancreatic Ductal Adenocarcinoma+4 more
Minia University194 enrolled1 locationNCT07155525
Recruiting
Phase 3
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Intrahepatic Cholangiocarcinoma
Shanghai Junshi Bioscience Co., Ltd.480 enrolled1 locationNCT05342194
Recruiting
Phase 2Phase 3
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Cholangiocarcinoma
Mara Veenstra, MD81 enrolled3 locationsNCT06355427
Recruiting
Phase 2Phase 3
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Biliary Tract CancerCholangiocarcinoma
Gruppo Oncologico del Nord-Ovest300 enrolled19 locationsNCT06037980
Recruiting
Phase 3
Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University80 enrolled1 locationNCT05823311
Recruiting
Phase 3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.200 enrolled87 locationsNCT05948475